Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma

ABSTRACT Tumour-derived exosomes (TEX) are a subset of extracellular vesicles (EVs) present in body fluids of patients with cancer. The role of this exosome subset in melanoma progression has been of interest ever since ex vivo studies of exosomes produced by melanoma cell lines were shown to suppress anti-melanoma immune responses. To study the impact of melanoma-derived exosomes (MTEX) present in patients’ plasma on melanoma progression, isolation of MTEX from total plasma exosomes is necessary. We have developed an immunoaffinity-based method for MTEX capture from plasma of melanoma patients. Using mAb 763.74 specific for the CSPG4 epitope uniquely expressed on melanoma cells, we separated MTEX from non-tumour cell-derived exosomes and evaluated the protein cargo of both fractions by quantitative flow cytometry. Melanoma-associated antigens were carried by MTEX but were not detectable in exosomes produced by normal cells. Separation of plasma-derived MTEX from non-MTEX provides an opportunity for future evaluation of MTEX as potential biomarkers of melanoma progression and as surrogates of melanoma in tumour liquid biopsy studies.

[1]  Alessandro Sciarra,et al.  Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. , 2017, Cancer letters.

[2]  D. Lyden,et al.  Unshielding Exosomal RNA Unleashes Tumor Growth And Metastasis , 2017, Cell.

[3]  Xiaojie Li,et al.  Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification , 2017, PloS one.

[4]  Zhiqiang Gao,et al.  Progress in Exosome Isolation Techniques , 2017, Theranostics.

[5]  Jennifer C. Jones,et al.  Flow Cytometric Analysis of Extracellular Vesicles. , 2017, Methods in molecular biology.

[6]  T. Whiteside.  Tumor-Derived Exosomes and Their Role in Tumor-Induced Immune Suppression , 2016, Vaccines.

[7]  A. Bosio,et al.  Melanoma Affects the Composition of Blood Cell-Derived Extracellular Vesicles , 2016, Front. Immunol..

[8]  G. Stamp,et al.  Tumor-Stromal Cell Communication: Small Vesicles Signal Big Changes. , 2016, Trends in cancer.

[9]  T. Whiteside.  Exosomes and tumor-mediated immune suppression. , 2016, The Journal of clinical investigation.

[10]  S. S. Tai.  Streptococcus pneumoniae Serotype Distribution and Pneumococcal Conjugate Vaccine Serotype Coverage among Pediatric Patients in East and Southeast Asia, 2000–2014: a Pooled Data Analysis , 2016, Vaccines.

[11]  T. Whiteside,et al.  Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets , 2016, Scientific Reports.

[12]  T. Whiteside,et al.  Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer , 2016, Journal of extracellular vesicles.

[13]  A. Bosio,et al.  A novel multiplex bead-based platform highlights the diversity of extracellular vesicles , 2016, Journal of extracellular vesicles.

[14]  Paolo Guazzi,et al.  Integrated isolation and quantitative analysis of exosome shuttled proteins and nucleic acids using immunocapture approaches. , 2015, Methods.

[15]  T. Whiteside,et al.  The potential of tumor-derived exosomes for noninvasive cancer monitoring , 2015, Expert review of molecular diagnostics.

[16]  Christian Pilarsky,et al.  Glypican-1 identifies cancer exosomes and detects early pancreatic cancer , 2015, Nature.

[17]  T. Whiteside,et al.  Isolation and Characterization of CD34+ Blast-Derived Exosomes in Acute Myeloid Leukemia , 2014, PloS one.

[18]  S. Ferrone,et al.  Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma. , 2014, Methods in molecular biology.

[19]  T. Whiteside.  Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). , 2013, Biochemical Society transactions.

[20]  Dan Mercola,et al.  Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer , 2012, PloS one.

[21]  Gema Moreno-Bueno,et al.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET , 2012, Nature Medicine.

[22]  Simon C Watkins,et al.  Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. , 2011, Cancer research.

[23]  P. Altevogt,et al.  Body fluid derived exosomes as a novel template for clinical diagnostics , 2011, Journal of Translational Medicine.

[24]  Carmen Visus,et al.  Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes1 , 2009, The Journal of Immunology.

[25]  Massimo Spada,et al.  High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients , 2009, PloS one.

[26]  G. Parmiani,et al.  Tumor-released microvesicles as vehicles of immunosuppression. , 2007, Cancer research.

[27]  S. Ferrone,et al.  Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. , 2004, Critical reviews in immunology.

[28]  M. P. Murphy.  Pharmacogenomics: a critical component of patient stratification during drug development , 2002, Expert review of molecular diagnostics.

[29]  S. Ferrone,et al.  Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. , 1992, Cancer research.

[30]  S Ferrone,et al.  Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. , 1989, The American journal of pathology.